Drugs / CD19-BCMA dual nanobody based CAR-T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07451236 | Mar 2026 → Jun 2027 expected | disease related to hematopoietic stem cell transplant | Chang Yingjun | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19-BCMA dual nanobody based CAR-T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07451236 ↗ |
| Modality | Cell therapy | “CD19-BCMA dual nanobody based CAR-T Cells” NCT07451236 ↗ |
| Target | CD19 | “CD19-BCMA dual nanobody based CAR-T Cells” NCT07451236 ↗ |